SCHEMBL5204876

SCHEMBL5204876

Cc1ccc(-c2nc(C)nn2-c2ccc(S(N)(=O)=O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 11/20 0.58
CA1 P00915 9/20 0.56
CA2 P00918 9/20 0.56
CA9 Q16790 9/20 0.56
CA4 P22748 5/20 0.56
CA12 O43570 4/20 0.56
PTGS1 P23219 3/20 0.56
CA5A P35218 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
PDPK1 O15530 2/20 0.56
CYP2C9 P11712 2/20 0.56
ALOX5 P09917 2/20 0.56
CA3 P07451 2/20 0.56
CA6 P23280 2/20 0.56
CA7 P43166 2/20 0.56
PTGES O14684 1/20 0.56
HDAC3 O15379 1/20 0.56
PDE5A O76074 1/20 0.56
ABCB11 O95342 1/20 0.56
MT-CO2 P00403 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205884 0.89 PTGS2 (0.59) PTGS2CA1CA2CA9CA4
SCHEMBL5205568 0.89 PTGS2 (0.62) PTGS2CA1CA2CA9CA4
SCHEMBL5205238 0.89 PTGS2 (0.73) PTGS2CA1CA2CA9CA4
SCHEMBL5201569 0.89 PTGS2 (0.62) PTGS2CA1CA2CA9CA4
SCHEMBL6884932 0.87 PTGS2 (0.62) PTGS2PTGS1CYP2C9ALOX5
SCHEMBL5206224 0.87 PTGS2 (0.60) PTGS2CA1CA2CA9CA4
SCHEMBL5204981 0.84 PTGS2 (0.65) PTGS2CA1CA2CA9CA4
SCHEMBL5201724 0.81 PTGS2 (0.45) PTGS2CA1CA2CA9CA4
SCHEMBL5205612 0.81 PTGS2 (0.61) PTGS2CA1CA2CA4PTGS1
SCHEMBL5202701 0.80 CA1 (0.53) PTGS2CA1CA2CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1290842-C Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP (KR) 2006-12-20 CN claimed
EP-1458706-A4 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP (KR) 2005-06-08 EP claimed
CN-1608060-A Diaryl 1,2, 4-triazole derivatives as highly selective cyclooxygenase-2 inhibitors CJ CORP (KR) 2005-04-20 CN claimed
US-20050075373-A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2005-04-07 US claimed
EP-1458706-A1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ Corp. (KR) 2004-09-22 EP claimed
WO-2003055875-A1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP. (KR) 2003-07-10 WO claimed
EP-1458706-B1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP (KR) 2007-07-11 EP disclosed
US-7169929-B2 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2007-01-30 US disclosed
CN-1290842-C Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP (KR) 2006-12-20 CN disclosed
US-7135572-B2 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP (KR) 2006-11-14 US disclosed
US-20060009495-A1 Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2006-01-12 US disclosed
EP-1458706-A4 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP (KR) 2005-06-08 EP disclosed
CN-1608060-A Diaryl 1,2, 4-triazole derivatives as highly selective cyclooxygenase-2 inhibitors CJ CORP (KR) 2005-04-20 CN disclosed
US-20050075373-A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor CJ CORP. (KR) 2005-04-07 US disclosed
EP-1458706-A1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ Corp. (KR) 2004-09-22 EP disclosed
WO-2003055875-A1 DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR CJ CORP. (KR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009495-A1 Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor PTGS1, PTGS2, PTGES2 PTGS2 2/4885CA1 1415/4885CA2 605/4885
US-20050075373-A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor PTGS1, PTGS2, PTGES2 PTGS2 2/4885CA1 1611/4885CA2 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.